Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status. 

Latvia’s Olainfarm has set out details of a five-year strategy called ‘Forward 2020-2025’ that it anticipates will “make internal processes more effective for sustainable growth.” While laying out its forecast for 2021, the company said that it has planned “significant investments for research and development, as well as the acquisition of products and modernization and digitalization.”

With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020. 

South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”